Electra Therapeutics, Inc. Common stock（ETRA）資訊與事件ETRAElectra Therapeutics, Inc. Common stock

Nscale Limited Files for IPO, Plans to List on NYSE

Nscale Limited has filed for an IPO and aims to list on the New York Stock Exchange, as Electra Therapeutics and Orion180 Insurance made their market debuts after pricing their offerings.LATEST IPOS AND DIRECT LISTINGS:Electra Therapeuticsopened on September 18 at $15. The late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer priced its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The deal size was increased to 23.3M shares of common stock from 21.7M shares and priced at the midpoint of the $14.00-$16.00 target range.Orion180 Insuranceopened on September 18 at $11.50. The company priced 20M shares at $12.00. The deal priced below the target range of $15.00-$17.00. Orion180 is a provider of homeowners and flood insurance solutions.RECENT SPAC IPOS:Leader's Advantage Acquisitionopened on September 18 at $9.96. Clear Street is acting as lead bookrunner and D. Boral Capital is acting as bookrunner for the offering.Rainier Acquisitionopened on August 27 at $10.02. Rainier is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company intends to focus its search on the global life sciences industries. Chardan is acting as the sole book-running manager for the offering.JATT III Acquisition Corp(JTTTT) opened on August 26 at $11. The ordinary shares trade on the Nasdaq Capital Market under the ticker symbol "JTTT". Guggenheim Securities is acting as sole book-running manager.Southern Cross Acquisition II Corp.opened on August 26 at $10. Once the securities comprising the units begin separate trading, the ordinary shares, warrants and rights are expected to be listed on Nasdaq under "SCAT," "SCATW," and "SCATR," respectively.PERFORMANCE:Prices as of 11 am ET on Monday, September 21Electra Therapeutics – up more than 8% at $14.35;Orion180 Insurance – down about 1% at 11.51.UPCOMING IPOS:Upcoming IPO and direct listings expected include Nscale, Altera, Brooks Automation, Aggreko, and CALM Chain.Clickto see upcoming IPO calendar on TipRanks.Nscale Limitedhas filed with the SEC for an initial public offering of its ordinary shares. The company intends to apply to list its ordinary shares on the New York Stock Exchange under the symbol "NSCL". Goldman Sachs, J.P. Morgan, Morgan Stanley are listed as the lead bookrunners.Alteraannounced that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public offering of its common stock. "The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed public offering remains subject to the completion of the SEC review process, as well as market and other conditions," Altera stated. Altera, which provides high-performance, programmable compute and connectivity solutions, is backed by Silver Lake and Intel.Brooks Automationannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.Aggrekohas applied to list its ordinary shares on the New York Stock Exchange under the symbol "AGKO." No amount has been given.CALM Chainhas filed for an initial public offering of 5M Class A ordinary shares, representing 24.39% of the company's total Class A ordinary shares issued and outstanding following completion of the offering. The company is offering, on a firm commitment basis, 5M Class A ordinary shares. Following the completion of the offering, 24.39% of the Class A ordinary shares issued and outstanding will be held by public shareholders, assuming the underwriter does not exercise the over-allotment option. The company expects the initial public offering price for the offering will be between $5.00 and $7.00 per Class A ordinary share and it plans to list its Class A shares on the Nasdaq Capital Market under the symbol "CCIL"."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.

Electra Therapeutics Upsizes IPO Price to $15

Electra Therapeutics, a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, priced its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The deal size was increased to 23.3M shares of common stock from 21.7M shares and priced at the midpoint of the $14.00-$16.00 target range.

Electra Therapeutics Prices IPO at $15 per Share

Electra Therapeutics, a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, priced its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The deal size was increased to 23.3M shares of common stock from 21.7M shares and priced at the midpoint of the $14.00-$16.00 target range. Jefferies, TD Cowen, Evercore ISI and Cantor Fitzgerald are acting as joint book running managers for the offering.